Wealth of nonexecutive chairman of $2 billion (revenue) generics maker Cipla took a hit as a cut in drug prices by the government impacted domestic revenue, causing shares to fall. The company appointed a new CEO and named Hamied's niece Samina Vaziralli as executive vice chairman in September. Cipla is expanding overseas, notably in South Africa, where a new $90 million plant to make biosimilar drugs will be built in Durban. Cipla is also one of a group of companies that successfully bid for drugs divested by Israel's Teva Pharmaceutical.
YK Hamied has public health on the top of his agenda. In his effort to make drugs affordable, he is not afraid to take on the biggies
Can India's pharma giants, who rose on the strength of chemistry, soar on the back of biology?
Indian pharma's dependence on Chinese imports can be reduced only by developing a domestic ecosystem that boosts and supports drug manufacturers
A sarangi player who is audible in a fusion rock band, Suhail Yusuf Khan, 26, is worth making a noise about
The executive VP of Cipla, on the leadership lessons that have helped her over the last decade
Cipla's YK Hamied is no ordinary business leader. He is a pioneer and a disruptor who has significantly changed the global pharma landscape in his over 50-year professional career
Speaking at the Forbes India Leadership Awards, the octogenarian pharma industry veteran stressed on the importance of democratizing access to affordable healthcare by increasing competition
In the premiere episode of Forbes India Leadership Mantras, Samina Hamied, executive vice-chairperson of Cipla, takes us through her decade-long journey in the company and talks about the challenges she faced along the way